(Q54443998)

29 May 2018

title

Why monitor peak vancomycin concentrations? (English)

1 reference

29 May 2018

1 reference

A MacGowan

1

1 reference

29 May 2018

A Lovering

series ordinal

2

1 reference

29 May 2018

L White

series ordinal

3

1 reference

29 May 2018

D Reeves

series ordinal

4

1 reference

29 May 2018

language of work or name

English

0 references

publication date

1 March 1995

1 reference

29 May 2018

published in

The Lancet

1 reference

29 May 2018

volume

345

1 reference

29 May 2018

issue

8950

1 reference

29 May 2018

page(s)

645; author reply 646-7

1 reference

29 May 2018

Therapeutic monitoring of antimicrobials: a summary of the information presented at the UK NEQAS for antibiotic Assays meeting for participants, October 1993

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990546-4

7 January 2021

Pharmacokinetics of vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990546-4

7 January 2021

The inhibitory quotient. A method for interpreting minimum inhibitory concentration data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990546-4

7 January 2021

Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990546-4

7 January 2021

How vancomycin is used in Australasia - A survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990546-4

7 January 2021

Survey of Vancomycin Monitoring Guidelines in Illinois Hospitals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990546-4

7 January 2021

Nephrotoxicity of vancomycin, alone and with an aminoglycoside

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990546-4

7 January 2021

Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990546-4

7 January 2021

Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990546-4

7 January 2021

Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990546-4

7 January 2021

In-vitro comparison of the post-antibiotic effect of vancomycin and teicoplanin.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990546-4

7 January 2021

Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990546-4

7 January 2021

Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990546-4

7 January 2021

10.1016/S0140-6736(95)90546-4

Identifiers

DOI

1 reference

29 May 2018

1 reference

29 May 2018